News Hub | News Direct

Technology

Artificial Intelligence Big Data Cloud Computing Cyber Security Data Management Electronics Enterprise & Network Technology Financial Technology Hardware Mobile & Wireless Nanotechnology Semiconductor Software Telecommunications
Article thumbnail News Release

Robot Dog Saves Lives in Massachusetts Standoff

MarketJar

A robotic dog named Roscoe from the Massachusetts State Police Bomb Squad is being praised for its role in averting a potential tragedy involving a person barricaded in a home. 1 On March 6, the Massachusetts State Police sent Roscoe into a home where a 30-year-old man, who had allegedly held his mother at knifepoint, was located. The suspect shot the robot three times, partially disabling it. State police noted that deploying Roscoe potentially saved the lives of officers and real dogs involved in the incident. Boston Dynamics, the company behind the Spot robot, stated that it was the first time one of their robots had been shot. The company expressed relief that the only casualty was their robot. Roscoe has been sent to Boston Dynamics for repairs, and a new unit will be provided to the state police. Robots are increasingly being used by law enforcement agencies nationwide. In New York City, Digidogs have been employed since 2023 to help de-escalate situations. Similarly, law enforcement agencies in Florida, Los Angeles, and other states have utilized these cybernetic hounds. 2 Another company deploying AI-powered robots and emergency systems to deter crime across the US is Knightscope, Inc. (NASDAQ:KSCP), a leading innovator in robotics and artificial intelligence (AI) technologies focused on public safety. Knightscope ’s autonomous security robots (ASRs) use a unique combination of self-driving technology, robotics, AI, and electric vehicles to provide humans with extra eyes, ears and a voice on the ground. Innovative Robot Company Progresses on Path to Profitable Expansion Knightscope deployed its first Autonomous Security Robots in May 2015 and has continued signing contracts since with major clients across the country. The company’s ASRs, Blue Light Tower emergency phones and Automated Gunshot Detection (AGD) technology is already being utilized in public spaces including schools, hospitals, HOAs, casinos, transportation hubs and places of worship. On April 4, Knightscope, Inc. (NASDAQ:KSCP) announced 18 new contracts and five new renewal agreements that are valued at over $1 million. The announcement comes off the back of a successful Innovation Week held by the company and its FY 2023 results, adding substantial growth in its top line revenue through new contracts. These contracts predominantly hail from rapidly expanding sectors like transportation, healthcare, education, and local government, which not only form the bulk of the current agreements but also offer numerous prospects for further expansion across both individual clients and their markets. Earlier this week, Knightscope, Inc. (NASDAQ:KSCP) reported its financial results for 2023, showcasing significant progress towards profitability and operational efficiency. Knightscope reported total revenue of $12.8 million, marking a substantial 128% increase from the previous year. This growth was driven by a $2 million increase in net revenue from services, totaling $7.2 million, and a $5.2 million increase in net revenue from product sales, totaling $5.6 million. The surge in product sales was attributed to the integration of Emergency Communication Devices (ECDs) into their product lines following the acquisition of CASE Emergency Management Systems. Total operating expenses for the year amounted to $24.3 million, a $4.4 million reduction from the previous year. This reduction was driven by lower sales and marketing costs and R&D expenses, leading to operating expenses as a percentage of revenue dropping from 509% to 190%. Looking ahead to 2024, Knightscope has outlined a growth strategy focused on organizational restructuring, service optimization, manufacturing consolidation, and facility reduction. These initiatives aim to reduce payroll expense by over 30%, align support for key technologies with service contracts, and improve manufacturing efficiency and facility utilization. Knightscope also plans to bolster its product offering further after signing an MOU with Draganfly (NASDAQ: DPRO), an award-winning industry leading drone developer. The company plans to integrate Draganfly’s drone technology with its ASR tech to create Autonomous Security Drones. For further information on Knightscope 's innovative solutions and projects, please visit Knightscope's website (NASDAQ:KSCP). Footnotes: [1] https://www.ctvnews.ca/mobile/world/robot-police-dog-shot-credited-with-averting-potential-tragedy-1.6825781?cache=sstyoxrk?clipId=89563 [2] https://www.usatoday.com/story/tech/2024/03/28/what-to-know-about-spot-the-robotic-dog/73118781007/ Disclosure: 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies outlined in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Knightscope, Inc. Market Jar Media Inc. was paid $1,500 for the production and publishing of this article by Knightscope, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.’s engagement by Knightscope, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-kscp. 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Knightscope, Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Knightscope, Inc.’s industry; (b) market opportunity; (c) Knightscope, Inc.’s business plans and strategies; (d) services that Knightscope, Inc. intends to offer; (e) Knightscope, Inc.’s milestone projections and targets; (f) Knightscope, Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Knightscope, Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Knightscope, Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Knightscope, Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Knightscope, Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) the accuracy of budgeted costs and expenditures; (e) Knightscope, Inc.’s ability to attract and retain skilled personnel; (f) political and regulatory stability; (g) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (h) changes in applicable legislation; (i) stability in financial and capital markets; and (j) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Knightscope, Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Knightscope, Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Knightscope, Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Knightscope, Inc.’s business operations (e) Knightscope, Inc. may be unable to implement its growth strategy; and (f) increased competition.Except as required by law, Knightscope, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Knightscope, Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Knightscope, Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Knightscope, Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Knightscope, Inc or such entities and are not necessarily indicative of future performance of Knightscope, Inc. or such entities. 8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

April 04, 2024 10:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

Classiq and Quantum Intelligence Corp (QIC, Korea) Partner On Quantum Accelerated Drug Development

Classiq Technologies

Classiq, a leading quantum computing software company, and Quantum Intelligence Corp. ( QIC, Korea ) today announced the launch of innovative joint research to accelerate drug development by applying quantum computing to pharmacology. The collaboration is under the auspices of Classiq’s Quantum Computing For Life Sciences & Healthcare Center, launched with NVIDIA last year. This new partnership is dedicated to utilizing the Classiq platform to explore the use of quantum computing in pharmacology for a wide range of predictive and analytical applications. This includes the discovery and design of novel drug candidates as well as the prediction of potential side effects and interactions. The partnership focuses on significantly enhancing the efficiency and accuracy of drug development by integrating Classiq's quantum computing platform with QIC's drug development platform. “Quantum Intelligence diverges from the traditional route of biopharmaceutical companies, positioning itself more as a platform company powered by quantum and AI technology,” stated QIC's CEO, Hwanho Choi, MD., PhD. “Through this unique collaborative approach, we aim to precisely identify potential side effects early on, reducing risks across all stages of drug development and clinical trials.” QIC, a South Korean startup pioneering the QUEST-ADMET platform based on quantum computing and AI technologies, targets prediction of compound properties through electronic charge distribution algorithms, to efficiently assess therapeutic solution efficacy and safety of drug candidates. Classiq offers a leading quantum development platform with unique technology enabling high-level abstraction that simplifies and accelerates development of efficient complex quantum software and applications. The Classiq platform’s built-in functions, GitHub repository and seamless execution on quantum computing hardware, will be key components in the research to develop pharmacology applications for research. “This agreement marks a significant step towards a new era of accelerated drug development using quantum computing technology,” said Classiq’s CEO Nir Minerbi. “By combining Classiq's quantum computing technology with QIC's drug development platform, we target significant improvements in the efficiency and accuracy of drug development.” About Classiq Classiq Technologies, the leading quantum software company, provides an all-encompassing platform (IDE, compiler and OS) with a single point of entry into quantum computing, taking users from algorithm design to execution. The high-level descriptive quantum software development environment, tailored to all levels of developer proficiency, automates quantum programming. This ensures that a broad range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of quantum physics. Classiq democratizes access to quantum computing and equips its users to take full advantage of the quantum computing revolution, including access to a broad range of quantum hardware. Classiq’s core technology, algorithmic quantum circuit compilation, is engineered to power the quantum ecosystem of today and the future. Classiq works closely with quantum cloud providers and advanced computation hardware developers providing software for use with quantum computers, HPC and quantum simulators. Backed by investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq’s world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking quantum engine. Follow Classiq on LinkedIn, X (formerly Twitter) or YouTube, and visit the Slack community and website, www.classiq.io to learn more. About Quantum Intelligence Corp. (QIC) Founded in 2020 by CEO Dr. Choi Hwanho and CTO Dr. Kang Hong-seok, Quantum Intelligence Corp. (QIC), based in Seoul, South Korea, is at the forefront of integrating quantum computing with artificial intelligence to revolutionize drug discovery. Using its advanced QUEST-ADMET platform and the Quantum-Dock module, QIC aims to outperform conventional drug development approaches in both accuracy and speed, offering highly precise predictions of drug efficacy and safety. QIC's global expansion is supported by strategic partnerships, including collaborations with Oxford Quantum Circuits (UK), Quandela (France), and QuEra Computing (US), alongside a joint venture with 48Hour Discovery (Canada). These partnerships enhance QIC's presence in key North American, European and Asian markets. The collaborations are aimed at improving pharmacological predictions, discovering new drug candidates and investigating metalloprotein-ligand interactions and pharmacokinetics. Beyond healthcare, QIC is also exploring quantum computing's potential in the financial sector, aiming to transform algorithmic trading, risk analysis and asset management. QIC's diverse team of experts in quantum physics, molecular modeling and AI is committed to driving innovations that optimize the drug development process. These efforts have established QIC as a prospective leader in quantum drug discovery, aiming to reduce development costs and timelines while improving drug safety and efficacy. The company's strategy to license out drug candidates developed with its quantum computing technology marks a paradigm shift in the pharmaceutical industry, underscoring Quantum Intelligence's potential for significant growth. Contact Details Rainier Communications on behalf of Classiq Michelle Allard McMahon classiqPR@rainierco.com Quantum Intelligence Corp. (QIC) Byung-Hoon Kim, Operations Manager hoon.kim@qic.ai Company Website http://www.classiq.io/

April 04, 2024 08:00 AM Eastern Daylight Time

Article thumbnail News Release

Bacula Systems Corp Appoints Aristide Caraccio as President & CEO

Bacula Systems

Expanding its leadership in high security backup and recovery for HPC and demanding IT environments, Bacula Systems today named Aristide Caraccio, its Senior VP of Sales and Marketing, as President & CEO of Bacula Systems Corp. “Aristide is a dynamic, values-driven business leader who has a diverse background of experiences and an excellent track record of delivery in the IT industry. He has led Bacula’s sales and marketing activities worldwide for some years now and helped build the industry leading reputation we have for customer satisfaction in some of the world’s most security conscious and demanding organizations worldwide. The Board looks to Aristide to further develop the organization to realize the full potential of Bacula Systems Corp, delivering growth and value for its customers, employees and shareholders”, said Frank Barker, Chairman of Bacula Systems SA. Caraccio joined Bacula in 2011, and has been instrumental in developing Bacula’s customer base in the United States and globally, including large organizations such as NASA, Warner Bros. Discovery and Navisite. “I am excited by Bacula’s unique ability to protect large, complex and high performance IT environments, and its disruptive positioning in helping users to avoid vendor lock-in. The opportunity for Bacula has never been bigger than it is today and I am honored to lead Bacula Systems Corp as it helps organizations to modernize their backup strategy, lower costs, and achieve much better protection against ransomware and other attacks”, said Caraccio. “I am delighted to have Aristide leading Bacula Systems Corp. His vision and drive will help us to bring a more secure, flexible, scalable, powerful and cost-effective backup and security solution to more customers so they can replace outdated and overpriced legacy backup systems. Aristide has the right industry and commercial knowledge to leverage our unique software and lead Bacula Systems Corp as it further develops market share in North America, Canada and Latin America”, said Gopal RajGuru, CEO of Bacula Systems SA. About Bacula Systems: Bacula Enterprise is a highly scalable backup and recovery software for large organizations, data centers and MSPs. www.baculasystems.com Contact Details Rob Morrison rob.morrison@baculasystems.com +41 21 641 60 80 rob.morrison@baculasystems.com Company Website https://www.baculasystems.com/

April 04, 2024 07:17 AM Eastern Daylight Time

Article thumbnail News Release

Upcoming ETF Verdict Spurs Crypto Buy Pressure: Bitcoin, Ethereum, and Raboo Set for Further Gains

Total Media

As anticipation mounts with the upcoming ETF verdict, the crypto market sees a surge in buy pressure. Bitcoin and Ethereum, already household names, are joined by the emerging contender Raboo, currently in the limelight with its presale. Priced at a mere $0.003, Raboo is not just any token—it's forecasted to skyrocket by 100x in 2024. With analysts buzzing over the Bitcoin price prediction and the potential approval of an Ethereum ETF, the stage is set for monumental gains. Raboo, in particular, stands at a pivotal 233% growth expectation during its presale, heralding an explosive entry into the crypto scene. Bitcoin's wild March: Highs, lows, and the unstoppable rise to the top Bitcoin's dance on the financial stage has been nothing short of a thriller this March. Hitting an all-time high, Bitcoin swiftly took a 10% tumble, causing a frenzy of over $1 billion in crypto liquidations​​. Yet, amidst this rollercoaster, the crypto titan stands resilient, buoyed by news of BlackRock's Bitcoin ETF potentially eclipsing Grayscale's holdings, setting the stage for a seismic shift in institutional holdings​​. With Bitcoin's halving on the horizon, the buzz around its future Bitcoin’s price performance intensifies, keeping enthusiasts on the edge of their seats​​. This unpredictability, combined with expert Bitcoin price predictions hinting towards $100,000, teases a future where Bitcoin's influence only grows stronger. Ethereum: Skyrocketing prices and groundbreaking upgrades unleashed Keeping up with the Bitcoin price prediction is Ethereum which has seen its recent trajectory sail past $3,500, invigorated by the upcoming potential approval of the Ethereum ETFs​​. The anticipation around Ethereum and its evolving ecosystem, including pivotal upgrades and market enthusiasm, positions Ethereum for an exhilarating leap forward. Ethereum, standing at the precipice of innovation, continues to captivate investors and developers alike. Raboo rises: A meme revolution unleashed, setting the digital world ablaze Raboo is set to redefine the meme landscape by marrying social-fi and AI, creating a dynamic arena for meme aficionados. This platform transforms users into vital contributors within a flourishing ecosystem of NFTs and AI-enhanced memes, fostering an unprecedented level of creative engagement. Raboo's narrative, a digital realm in 3024 overrun by mundane memes, sets the stage for its rise as the savior of digital creativity, wielding an AI capable of evolving and curating high-quality content. The RABT token, beyond mere trading, acts as the backbone of this community, incentivizing participation through challenges and exclusive giveaways. The anticipation around its presale, priced attractively at $0.003, hints at a 366% growth potential before launch, aiming for a spectacular 100x increase on debut. Raboo's vision extends to eclipsing giants like Shiba Inu and Dogecoin, propelled by a unique tokenomics strategy, including a deliberate crypto burn to enhance value. With features like Rabooscan and exclusive NFTs for early supporters, Raboo is a unique long-term investment opportunity for crypto enthusiasts. Conclusion As the crypto market heats up with the impending ETF decisions for Ethereum, the spotlight intensifies on Raboo. With its presale quickly selling out, Raboo represents a fleeting, golden opportunity for early investors. This surge of interest underscores the urgency and potential of Raboo, alongside stalwarts like Bitcoin and Ethereum, as they head toward unprecedented growth. You can participate in the Raboo presale here. Contact Details Total Media Solutions media@Totalsolutionspr.io

April 03, 2024 03:25 PM Eastern Daylight Time

Image
Article thumbnail News Release

AdvicePay 2024 Fee-for-Service Industry Trend Report Shows Marked Increase in Fees Advisors Charge for Fee-Based Financial Planning

AdvicePay

In 2023, financial advisors saw an increase in the amount of fees they were able to charge clients who engaged them in fee-for-service financial planning, according to the 2024 Fee-for-Service Industry Trend Report from AdvicePay, the industry-leading platform for processing payments and overseeing compliance of fee-for-service financial planning. Last year, monthly recurring subscriptions for planning fees rose to $265 per client, up 6% from 2022. Quarterly recurring subscriptions averaged $968 per client, up 1.6%. One-time payments rose 6.7% to $1,578, according to AdvicePay’s proprietary data. Financial advisors continue to prefer subscription models. According to the report, 83% of all invoices sent through AdvicePay were for subscriptions, and 74% of all invoices were monthly recurring. Half of all advisors bill their clients monthly, while 22% bill quarterly. Advisors reported that clients remain receptive to fee-for-service financial planning because it aligns with their accustomed payment models for other subscription services, such as Netflix. This approach enables them to conveniently compensate their advisors using their cash flow while adding an extra layer of transparency. “We continue to find that there are more consumers looking for financial planning than there are financial planners to provide that fee-for-service offering,” said Alan Moore, Co-Founder and Chief Executive Officer of AdvicePay. “What’s more, the retention rates are extremely high in an ongoing financial planning relationship, and the latest data show that the economics continue to be very favorable.” According to research issued by Cerulli Associates and the Securities Industry and Financial Markets Association (SIFMA), there has been a notable shift, with 63% of investors expressing a willingness to pay for advice, up from the 38% reported in 2009. The research also highlights a heightened demand for personalized, comprehensive advice with a focus on formal financial plans rising from 38% to 54% over the past 14 years. Most advisors surveyed offer additional services outside of fee-based planning. According to the data, 88.4% offer investment management, while 82.1% provide tax planning. Increasingly, more advisors are offering guidance on held-away accounts like 401(k)s, with 63.1% of financial advisors reporting this is a service they provide. The 2024 AdvicePay Fee-for-Service Industry Trend Report draws upon insights gleaned from over 380,000 fee-for-service financial planning transactions conducted through the company’s platform. To receive a copy of the full report, please visit https://info.advicepay.com/trends. About AdvicePay Established by well-known financial advisors Michael Kitces and Alan Moore, AdvicePay is the industry-leading billing and payment workflow solution created specifically for fee-for-service financial planning. Financial services firms and their advisors benefit from efficient workflows designed exclusively to support their fee-for-service financial planning revenue, including up-to-date compliance and data security management, all in one unified platform. Contact Details Shannon Beck +1 406-412-2047 media@advicepay.com Company Website https://advicepay.com/

April 03, 2024 01:22 PM Eastern Daylight Time

Article thumbnail News Release

MedCognetics Secures Groundbreaking Patent for Inclusive, Unbiased Medical Imaging AI Technology in Mammography

MedCognetics

In a significant stride towards equitable healthcare technology, MedCognetics, Inc., a company focusing on medical imaging AI, today announced it has been awarded patent number 11,948,297 by the United States Patent and Trademark Office (USPTO). The patent covers architectural strategies and methodologies for achieving unbiased AI in breast imaging. This innovation is backed by MedCognetics’ peer-reviewed publications in industry conferences such as the Radiological Society North America (RSNA) 2023, the European Society of Radiology (ESR) 2024, and a grant from the National Institutes of Health (NIH). This breakthrough is set to redefine the development of AI in the medical field ensuring MedCognetics’ algorithms maintain high performance across different patient demographics, thereby guaranteeing consistent, fair, superior patient outcomes. "This patent is a reflection of our team's focused pursuit of innovation and commitment to inclusivity,” said Ron Nag, CEO of MedCognetics, Inc. “Our technology is not just about improving patient outcomes through earlier and more accurate diagnoses; the focus is on fostering equality in technological development and ensuring universal access to advancements in healthcare systems worldwide. We remain dedicated to progressing in the field of unbiased medical imaging technology.” MedCognetics is actively engaged in partnerships with leading healthcare institutions and research organizations to bring its patented AI technology into clinical practice, aiming for widespread patient benefit from these advancements at the earliest. Full details of the allowance are listed in the Issue Notification Certificate issued by the USPTO. For further information about MedCognetics and its pioneering medical imaging AI technology, please visit www.medcognetics.com. About MedCognetics, Inc. MedCognetics provides an advanced AI software platform that integrates into radiology workflow. In addition, the AI algorithm is trained on a diverse global patient dataset to mitigate data biasing. The future of AI in healthcare is unbiased services and MedCognetics is at the forefront of creating a more predictable medical outcome and ultimately saving lives. Founded in 2020, the company is based in Dallas, Texas. For more information, please visit our website at www.medcognetics.com. Contact Details ANW Networks Alicia Nieva-Woodgate +1 415-515-0866 alicia@anwnetworks.com Company Website https://www.medcognetics.com

April 03, 2024 11:30 AM Eastern Daylight Time

Article thumbnail News Release

Nextech3D.ai protects intellectual property with a patent for generating 3D models from 2D images

Nextech3D.AI

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to announce a significant milestone for the company as the U.S. Patent and Trademark Office (USPTO) officially issued a patent for their technology to generate three-dimensional models from two-dimensional images. Gappelberg emphasized the importance of this patent in the realm of artificial intelligence (AI) and 2D to 3D model generation, describing it as a pivotal patent for the 3D modeling industry. He highlighted that this patent adds substantial value to Nextech3D.ai and positions the company as one of the technology leaders in the field of converting 2D photos to 3D models using AI. The issuance of this patent provides Nextech3D.ai with a competitive advantage, setting them apart from other companies involved in 3D model generation. Gappelberg expressed confidence that this patent, along with a second AI patent issuance and seven additional patents filed, strengthens the company's position and builds a moat around their 3D model-making business for e-commerce. With a focus on both industry expertise and intellectual property, including GPT AI-powered 3D model generation, Nextech3D.ai aims to increase shareholder value by investing in 3D-AI GPT patents and solutions. Gappelberg emphasized that this second AI patent approval reinforces and validates the company's commitment to innovation and generating substantial revenue through 3D modeling. Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

April 03, 2024 11:20 AM Eastern Daylight Time

Video
Article thumbnail News Release

PathAI Announces Research Presentations at the 2024 AACR Annual Meeting

PathAI

PathAI, Inc., a leading AI-powered precision pathology company, today announced it will present research from its portfolio of oncology products at the AACR Annual Meeting on April 7-10, 2024, in San Diego, CA. The research demonstrates how machine learning models developed to characterize the tumor microenvironment (TME) from routine hematoxylin and eosin (H&E)-stained whole slide images (WSIs) can be used to advance biomarker development and precision medicine strategies. The presentations include new research leveraging PathAI’s pan-tumor foundation models and its commercially available product, PathExplore 1, to identify key histologic features associated with molecular signatures and patient response to therapy. Highlights: Researchers deployed PathExplore on HNSCC and NSCLC samples to characterize the cell and tissue composition of the tumor microenvironment, as well as compute immune phenotypes directly from H&E WSI. (Poster #905 ) Researchers from Incendia Therapeutics developed a continuous scoring method for Discoidin Domain Receptor 1 (DDR1), which revealed widespread immune exclusion in tumors based on the spatial distribution of lymphocytes, CD8+ T cells, and CD45+ immune cells from H&E and mIF images. DDR1 is highly expressed in epithelial cancers and has been implicated in tumor growth, invasion, and lack of response to therapy. The immune exclusion score correlates with DDR1 mRNA and protein expression. The study provides additional insight into the role of DDR1 in human cancers and may be useful in selecting indications and stratifying patients for DDR1-targeted therapies. (Poster #2916 ) Using unsupervised learning driven by PathExplore’s features and a novel collagen fiber detection imaging technology, researchers discovered three distinct phenotypes of cancer associated stroma (CAS) that had distinct patterns of association with survival and gene expression signatures. Two of them were enriched in collagen fiber density as well as in density of fibroblasts, while the third phenotype had the highest density of immune cells, providing a categorization of different types of CAS-tumor interaction that may be useful for patient stratification. (Poster #4912 ) Using AI-powered models from PathAI, Foundation Medicine researchers investigated digital pathology TME features of immunotherapy outcomes among NSCLC patients within a real-world dataset from the Flatiron Health-Foundation Medicine Clinico-Genomic Database. These results indicate that the composition of the TME assessed via digital pathology may have utility in identifying NSCLC patients who will respond to first-line immune checkpoint inhibitors beyond the established immunotherapy biomarkers. (Poster #4969 ) In collaboration with EMD Serono, AI-powered TME models from PathAI were used to analyze H&E WSI of NSCLC from a randomized Phase 3 trial directly comparing two immunotherapies. Researchers compared cell abundance features with gene expression data from the same samples and found that immune and stromal cell abundance features were associated with expression of genes in relevant cellular pathways, confirming the biological relevance of our cellular features. In analyzing the features alongside the clinical data from the retrospective study, researchers identified candidate prognostic immunotherapy biomarkers. (Poster #6179 ) Researchers from Incendia Therapeutics illustrated that morphologic features derived from H&E images using PathExplore can be effective predictors of CD8-defined immune exclusion, providing an option for patient stratification by immune phenotype using widely available H&E images. The features and direction of association align with prior knowledge of the mechanism or manifestations of immune exclusion or infiltration in the TME, including the relative density of lymphocytes in tumor and stroma. (Poster #7392 ) PathAI’s pan-tumor foundation models were used to identify tissue regions and cell types on H&E WSI to quantify tumor purity across multiple tumor types. Model-derived tumor purity estimates were compared to three orthogonal molecular methods of purity and found to correlate across disease indications. These results provide evidence of how AI can improve the efficiency of molecular testing and enhance precision diagnostic strategies. (Poster #7402 ) Follow PathAI on LinkedIn and X for more updates from #AACR24 and visit us in person at booth #1549. 1 PathExplore is For Research Use Only. Not for use in diagnostic procedures. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to have a team of 600+ innovative thinkers from around the globe. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

April 03, 2024 10:00 AM Eastern Daylight Time

Article thumbnail News Release

Analyst Crypto Jebb Urges To Buy Ethereum Right Now! Cardano Left in the Dust As KangaMoon Bull Run Continues!

Kangamoon

Renowned analyst Crypto Jebb has been talking about Ethereum (ETH) a lot lately and people are starting to listen. Meanwhile, Cardano (ADA) has been outshined by many altcoins like KangaMoon (KANG), which is on a massive bull run. This Stage 5 presale star has already provided early buyers with 291% ROI, causing many experts to hint at a $0.5 price in 2024. Crypto Jebb: Ethereum Price Will Moonshot Recently, Ethereum (ETH) has been on an uptrend. Over the past 30 days, the Ethereum price soared from $3,409 to $3,557. During that time, its market cap increased from $410B to $427B. According to crypto analyst Crypto Jebb, this bullish trend will continue for the Ethereum crypto. He forecasts a potential 10x on ETH within the next ten years. This altcoin's technical analysis also shows a bullish future. For instance, Ethereum is now trading above its 100— and 200-day EMAs. Additionally, 25 technical indicators are showing green for ETH. As a result, experts have made a bullish Ethereum price prediction. They foresee this altcoin's price hitting $4,489 within Q2 of 2024. Cardano (ADA): Trading in the Red On the other hand, Cardano (ADA) has been trading in the red. According to CoinMarketCap data, the Cardano price sank from $0.73 to $0.63 over the past month. In that period, its market cap also fell from $26B to $22.46B. However, the technical analysis for this altcoin paints a different picture. Notably, the Cardano coin is trading above its 100 and 200-day EMAs. Additionally, this altcoin now has over 20 technical indicators showing bullish signs. Due to all these reasons, market analysts have made a bullish Cardano price prediction - a rise to $0.86 within Q2 of 2024. KangaMoon (KANG): Becoming One of the Altcoins To Watch While Ethereum and Cardano experience ups and downs, KangaMoon (KANG) has surfaced as an unexpected contender. This presale star has already soared by 291%, with 20,000 registered community members. Moreover, KangaMoon has raised over $3.9M and projects reaching $5M before April 2024 ends. Essentially, KangaMoon will develop a Play-to-Earn (P2E) game in which KANG will serve as the main in-game currency. With KANG, you can buy character upgrades or in-game items. Additionally, KANG holders gain exclusive access to challenges for extra tokens or in-game items. Another impressive part of KangaMoon is its dedication to cultivating an active community. As an example, users can earn free KANG tokens by being engaged members before the official launch. This has caused a significant surge in social media interaction as traders eagerly like, share and retweet KangaMoon's content. All these factors have helped KangaMoon obtain over 5,800 holders. Currently, one KANG token costs just $0.0196 - a 291% rise from its starting price of $0.005. Experts remain bullish as they forecast a rise to $0.5 once a Tier-1 CEX lists this altcoin in Q2 of 2024. This price prediction seems plausible with ties to the P2E gaming market, which will reach $885M by 2028. Will KangaMoon Rise Faster than Ethereum and Cardano? With its low $14M market cap, KangaMoon could outshine Ethereum and Cardano. This means it needs fewer new funds so the price can skyrocket faster. If you want to buy one of the top altcoins, sign up for its presale using the links below and get a 10% bonus. Discover the Exciting Opportunities of the KangaMoon (KANG) Presale Today! Website: https://Kangamoon.com/ Join Our Telegram Community: https://t.me/Kangamoonofficial Integrating GameFi and Play To EarnEmbark on your quest for glory. Assemble your champions, engage in epic battles or bet on your favorite fighters to earn $KANG tokens and exclusive rewards. Gain control of rare NFTs, unlock exclusive content and build alliances with fellow gamers as you ascend the ranks and leaderboards. Disclaimer: The following disclaimer is important to read and understand before engaging with Kangamoon, a play-to-earn meme coin. By accessing or participating in any activities related to Kangamoon, you acknowledge and accept the terms outlined below: 1 No Financial Advice: This whitepaper and any associated content do not constitute financial advice, investment recommendations, or solicitation to purchase Kangamoon tokens. The information provided is for informational purposes only. It is your responsibility to conduct thorough research and seek professional advice before making any financial decisions. 2 Volatility and Risks: Cryptocurrencies, including Kangamoon, are volatile and subject to significant price fluctuations. Investing in or holding Kangamoon tokens involves substantial risks, including the possibility of total loss. Past performance is not indicative of future results. 3 Regulatory Compliance: The regulatory environment surrounding cryptocurrencies is evolving and varies across jurisdictions. It is your responsibility to ensure compliance with applicable laws and regulations in your country or region before engaging with Kangamoon. 4 Uncertain Market: The market for meme coins and play-to-earn platforms is highly speculative and subject to rapid changes. There is no guarantee of market demand, liquidity, or utility for Kangamoon tokens. Token values may fluctuate drastically and may not reflect the intrinsic value of the project. By continuing to engage with Kangamoon, you acknowledge and accept the risks and limitations outlined in this disclaimer. You should only participate if you fully understand and are willing to assume these risks. Contact Details Kangamoon marketing@kangamoon.com Company Website https://kangamoon.com/

April 03, 2024 09:00 AM Central Daylight Time

Image
1 ... 7778798081 ... 599